Sylvia Herter
Research Subjects
Sylvia Herter has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Christian Klein
Faculty for Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
110 shared publications - Marina Bacac
Roche Innovation Center Zurich, Schlieren, Switzerland
109 shared publications - Emilio Yángüez
Roche Innovation Center Zurich, Schlieren, Switzerland
107 shared publications - Pablo Umaña
Roche Innovation Center Zurich, Schlieren, Switzerland
107 shared publications - Tamara Hüsser
Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland
107 shared publications - Stefanie Briner
Roche Innovation Center Zurich, Schlieren, Switzerland
106 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by American Society of Hematology in Blood Advances
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma
T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these challenges ask for new approaches to optimize treatment and to eventually understand resistance mechanisms. This phase 1 study (NCT04557150) investigated mode of action and resistance mechanisms of forimtamig, a novel GPRC5DxCD3 TCB. Biomarker analyses included deep phenotyping of patients' tumor and immune cells, functional T cell characterization, cytokine release, soluble B-cell maturation antigen kinetics and minimal residual disease evaluation. Biomarker data analysis assessed the impact of different TCB treatment approaches on T cell-mediated tumor killing dynamics: subcutaneous vs intravenous administration, weekly vs every 4 days step-up dosing, and low vs high target doses. A machine learning model revealed T-to-natural killer (NK)cell ratio in blood and bone marrow as a strong predictor of response. Single cell transcriptomics showed increased DNA repair and proliferation as major tumor hallmarks associated with resistance, while T cell dysfunction signatures were not predictive of response. T cells from non-responding patients showed an increased cytokine release when exposed to higher forimtamig exposure in an ex vivo setting. T cells from responding and non-responding patients were equally fit in killing tumor cells ex vivo. Our results highlight that forimtamig treatment optimization may be possible by boosting T cell numbers over NK cells, targeting tumor intrinsic resistance mechanisms or individualized dosing approach.
- 16 September 2026
- Published by American Society of Hematology in Blood Advances
Open AccessT-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma
T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these challenges ask for new approaches to optimize treatment and to eventually understand resistance mechanisms. This phase 1 study (NCT04557150) investigated mode of action and resistance mechanisms of forimtamig, a novel GPRC5DxCD3 TCB. Biomarker analyses included deep phenotyping of patients' tumor and immune cells, functional T cell characterization, cytokine release, soluble B-cell maturation antigen kinetics and minimal residual disease evaluation. Biomarker data analysis assessed the impact of different TCB treatment approaches on T cell-mediated tumor killing dynamics: subcutaneous vs intravenous administration, weekly vs every 4 days step-up dosing, and low vs high target doses. A machine learning model revealed T-to-natural killer (NK)cell ratio in blood and bone marrow as a strong predictor of response. Single cell transcriptomics showed increased DNA repair and proliferation as major tumor hallmarks associated with resistance, while T cell dysfunction signatures were not predictive of response. T cells from non-responding patients showed an increased cytokine release when exposed to higher forimtamig exposure in an ex vivo setting. T cells from responding and non-responding patients were equally fit in killing tumor cells ex vivo. Our results highlight that forimtamig treatment optimization may be possible by boosting T cell numbers over NK cells, targeting tumor intrinsic resistance mechanisms or individualized dosing approach.
- Open Access
- 16 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3259-3267
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial
There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Part 2 of the current study was an open-label, nonrandomized, phase 1 study of escalating doses of the CD19–4-1BBL co-stimulatory molecule, englumafusp alfa, in combination with glofitamab in patients with relapsed or refractory B-NHL. Obinutuzumab pretreatment was administered 7 days before the first glofitamab dose. Glofitamab step-up dosing in cycle 1 was followed by 11 cycles of glofitamab plus englumafusp alfa. Englumafusp alfa was administered at escalating doses, with the initial dose on cycle 2 day 8 (C2D8) or cycle 1 day 10 (C1D10). Primary objectives were to establish the maximum tolerated dose, and safety and tolerability. A total of 134 patients were enrolled, including 109 with aggressive B-NHL and 25 with indolent B-NHL. The maximum tolerated dose of englumafusp alfa was not reached; one dose-limiting toxicity occurred (grade 5 Pneumocystis jirovecii pneumonia). Adverse events were reported in 98.5% of all patients, with grade 3/4 adverse events in 59.0%. Grade 5 adverse events occurred in ten patients. In the subgroup of C2D8 patients with aggressive B-NHL (n = 83), overall response and complete metabolic response rates were 68.7% and 56.6%, respectively; among those without previous exposure to chimeric antigen receptor T cell therapy (n = 41), the corresponding rates were 73.2% and 65.9%. Pharmacodynamic changes following englumafusp alfa administration supported its co-stimulatory mode of action. These data demonstrate that the addition of englumafusp alfa to glofitamab is associated with encouraging efficacy and robust pharmacodynamic modulation, as well as a safety profile consistent with glofitamab monotherapy, in patients with relapsed or refractory B-NHL. CTIS identifier: 2022-502616-37-00; ClinicalTrials.gov identifier: NCT04077723.
- 16 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3259-3267
Open AccessEnglumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial
There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Part 2 of the current study was an open-label, nonrandomized, phase 1 study of escalating doses of the CD19–4-1BBL co-stimulatory molecule, englumafusp alfa, in combination with glofitamab in patients with relapsed or refractory B-NHL. Obinutuzumab pretreatment was administered 7 days before the first glofitamab dose. Glofitamab step-up dosing in cycle 1 was followed by 11 cycles of glofitamab plus englumafusp alfa. Englumafusp alfa was administered at escalating doses, with the initial dose on cycle 2 day 8 (C2D8) or cycle 1 day 10 (C1D10). Primary objectives were to establish the maximum tolerated dose, and safety and tolerability. A total of 134 patients were enrolled, including 109 with aggressive B-NHL and 25 with indolent B-NHL. The maximum tolerated dose of englumafusp alfa was not reached; one dose-limiting toxicity occurred (grade 5 Pneumocystis jirovecii pneumonia). Adverse events were reported in 98.5% of all patients, with grade 3/4 adverse events in 59.0%. Grade 5 adverse events occurred in ten patients. In the subgroup of C2D8 patients with aggressive B-NHL (n = 83), overall response and complete metabolic response rates were 68.7% and 56.6%, respectively; among those without previous exposure to chimeric antigen receptor T cell therapy (n = 41), the corresponding rates were 73.2% and 65.9%. Pharmacodynamic changes following englumafusp alfa administration supported its co-stimulatory mode of action. These data demonstrate that the addition of englumafusp alfa to glofitamab is associated with encouraging efficacy and robust pharmacodynamic modulation, as well as a safety profile consistent with glofitamab monotherapy, in patients with relapsed or refractory B-NHL. CTIS identifier: 2022-502616-37-00; ClinicalTrials.gov identifier: NCT04077723.
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Binding contributions of the PD-1 and LAG-3 arms of tobemstomig.
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Binding contributions of the PD-1 and LAG-3 arms of tobemstomig.
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig maintains long-term stem-like T cells and their progeny
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig maintains long-term stem-like T cells and their progeny
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo and ex-vivo preferential binding of tobemstomig
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo and ex-vivo preferential binding of tobemstomig
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In vivo tobemstomig preferentially binds and expands CD8 TILs including PD-1+ TCF-1+ stem-like T cells and drives their differentiation toward cytotoxic effectors. In vivo efficacy study and immunopharmacodynamic in human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors treated for 2 weeks with the indicated treatments. A, Tumor growth curves (n = 12 mice per treatment group; mean ± SEM). B and C, Representative contour plots of frequencies of CD8 and CD4 TILs (top), PGLALA+ PD-1+ CD8+ TILs (middle), and PGLALA+ PD-1+ CD4+ TILs (bottom) in one mouse of four. D, Pie chart depicting dose-dependent binding of tobemstomig as PGLALA+, available target, and target-negative cells within CD8 and CD4 TILs. E–L, Immunopharmacodynamic analysis of the effect of tobemstomig vs. parental anti–PD-1 (aPD-1) on (E) CD8, (F) CD4 T cells, and (G) Treg counts within the tumor microenvironment, (H) CD8:Treg ratio, (I) frequencies of PD-1+ CD8 TILs, (J) amount of stem-like (PD-1+ TCF-1+) CD8 T cells, and (K and L) progeny (n = 4; box plots represent median, minimum/maximum, and individual points). Statistical comparisons were performed using one-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In vivo tobemstomig preferentially binds and expands CD8 TILs including PD-1+ TCF-1+ stem-like T cells and drives their differentiation toward cytotoxic effectors. In vivo efficacy study and immunopharmacodynamic in human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors treated for 2 weeks with the indicated treatments. A, Tumor growth curves (n = 12 mice per treatment group; mean ± SEM). B and C, Representative contour plots of frequencies of CD8 and CD4 TILs (top), PGLALA+ PD-1+ CD8+ TILs (middle), and PGLALA+ PD-1+ CD4+ TILs (bottom) in one mouse of four. D, Pie chart depicting dose-dependent binding of tobemstomig as PGLALA+, available target, and target-negative cells within CD8 and CD4 TILs. E–L, Immunopharmacodynamic analysis of the effect of tobemstomig vs. parental anti–PD-1 (aPD-1) on (E) CD8, (F) CD4 T cells, and (G) Treg counts within the tumor microenvironment, (H) CD8:Treg ratio, (I) frequencies of PD-1+ CD8 TILs, (J) amount of stem-like (PD-1+ TCF-1+) CD8 T cells, and (K and L) progeny (n = 4; box plots represent median, minimum/maximum, and individual points). Statistical comparisons were performed using one-way ANOVA with the Tukey multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo dose dependent preferential binding of tobemstomig
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
In-vivo dose dependent preferential binding of tobemstomig
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig is refractory to drug-shaving by macrophages
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Tobemstomig is refractory to drug-shaving by macrophages
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral stem-like T cells retain their profile upon tobemstomig treatment
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral stem-like T cells retain their profile upon tobemstomig treatment
- Open Access
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral PD-1+ TCF-1+ stem-like CD8 T cells retain their transcriptional characteristics upon treatment with mu-tobemstomig. Immunopharmacodynamic study on the effect of different therapies, given three times, on amounts, phenotype, effector function, and molecular signature of intratumoral CD8 T cells obtained from human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors. A, Representative contour plots of the frequencies of PD-1+ CD8 TILs expressing TCF-1 (stem-like) vs. TIM-3 (progeny). Amounts of intratumoral PD-1+ CD8 TILs expressing TCF-1 vs. TIM-3 (B) at day 28 and (C) day 37 (n = 4, stacked bars; mean ± SEM). D, Two-dimensional Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) visualization of CD8+ TILs colored according to the subset (left) and specific treatment effect (right). E, Expression of selected markers and signatures among CD8+ TILs using a 2D UMAP visualization. F, Average signature enrichment scores among CD8 T cells per treatment group and individual animal (3–4 mice per group; box plots represent median, minimum/maximum, and individual points). G, Pie chart represents relative cell-type composition per treatment group.
- 9 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
Intratumoral PD-1+ TCF-1+ stem-like CD8 T cells retain their transcriptional characteristics upon treatment with mu-tobemstomig. Immunopharmacodynamic study on the effect of different therapies, given three times, on amounts, phenotype, effector function, and molecular signature of intratumoral CD8 T cells obtained from human PD-1 and human LAG-3 double transgenic mice bearing subcutaneous Panc02-H7-Fluc tumors. A, Representative contour plots of the frequencies of PD-1+ CD8 TILs expressing TCF-1 (stem-like) vs. TIM-3 (progeny). Amounts of intratumoral PD-1+ CD8 TILs expressing TCF-1 vs. TIM-3 (B) at day 28 and (C) day 37 (n = 4, stacked bars; mean ± SEM). D, Two-dimensional Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) visualization of CD8+ TILs colored according to the subset (left) and specific treatment effect (right). E, Expression of selected markers and signatures among CD8+ TILs using a 2D UMAP visualization. F, Average signature enrichment scores among CD8 T cells per treatment group and individual animal (3–4 mice per group; box plots represent median, minimum/maximum, and individual points). G, Pie chart represents relative cell-type composition per treatment group.